CompletedPhase 4

Treatment's Duration of Acute Uncomplicated Pyelonephritis

France310 participantsStarted 2009-06

Plain-language summary

The purpose of this study is to compare the efficacy of 5 days versus 10 days treatment duration in uncomplicated acute pyelonephritis. Acute pyelonephritis is a common disease and the treatment duration is not found on scientific evidence. If a short treatment is equal to standard duration, it will possible to shortening antibiotherapy with ecologic and economic advantage.

Who can participate

Age range

18 Years – 65 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women 18 to 65 years old * Non-immunocompromised * Conducting a medical examination prior * Signature of informed consent in writing. * Clinical signs of urinary tract infection (urinary burning, urgency, pollakiuria, dysuria, pyuria, lumbar or pelvic pain), * A temperature\> 38 ° C, * A positive ECBU direct seed (s) sensitive (s) to the fluoroquinolones Exclusion Criteria: * Antibiotic therapy prior * Presence of complications of PNA (abscesses, dilated excretory pathways, probe urinary bladder, neurological, transplant, kidney single functional or anatomical), * An episode of PNA within 6 months, * having fluoroquinolones in 6 months, * Infection on urinary endo-material (prosthetic urethral, ureteral probe) * The immunodepressed (known seropositivity for HIV, asplenia, diabetes neutropenia, agammaglobulinemia ...) * Pregnancy and lactation, * Allergy to antibiotics, * Corticosteroids concomitantly taking fluoroquinolones, * History of TENDINOPATHY with a fluoroquinolone * History of epilepsy * Deficit known as glucose-6-phosphate dehydrogenase * Life expectancy \<1 month * Cognitive major * Patient under guardianship, CURATORSHIP or without coverage, * The need for immunosuppressive or corticosteroid therapy, * The need for other concomitant antibiotic treatment, whatever the cause * No affiliation to a social security scheme (beneficiary or beneficiary).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Compare the rates of clinical and microbiological cure at 30 ± 5 days of the end of antibiotherapy in acute uncomplicated pyelonephritis of young women, according to the duration of antibiotherapy: 5 days versus 10 days.

Timeframe: 35 DAYS

Trial details

NCT IDNCT00873626

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-08

View on ClinicalTrials.gov More Urinary Tract Infection trials